Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Thorsten Schlomm

Hans Lehrach

Guido Sauter

Michal Schweiger

Holger Sueltmann

Stefan Boerno

Holger Sültmann

Stefan Börno

The invention relates to the identification and selection of novel genomic regions (biomarker) and the identification and selection of novel genomic region combinations which are hypermethylated in subjects with prostate cancer compared to subjects without prostate cancer. Nucleic acids which selectively hybridize to the genomic regions and products thereof are also encompassed within the scope of the invention as are compositions and kits containing said nucleic acids and nucleic acids for use in diagnosing prostate cancer. Further encompassed by the invention is the use of nucleic acids which selectively hybridize to one of the genomic regions or products thereof to monitor disease regression in a patient and the efficacy of therapeutic regimens.

Prostate cancer markers

Growing community of inventors

Hamburg, Germany

Thorsten Schlomm